Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016

  • ID: 3753830
  • Report
  • 286 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Astellas Pharma Inc.
  • Celgene Corporation
  • Immunomedics, Inc.
  • Juno Therapeutics Inc.
  • Novartis AG
  • MORE
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016

Summary

‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)
- The report reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
- The report assesses Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Astellas Pharma Inc.
  • Celgene Corporation
  • Immunomedics, Inc.
  • Juno Therapeutics Inc.
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Refractory Chronic Lymphocytic Leukemia (CLL) Overview

Therapeutics Development

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies

Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes

Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development

4SC AG

AbbVie Inc.

Arno Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

F. Hoffmann-La Roche Ltd.

Hutchison MediPharma Limited

ImmunoGen, Inc.

Immunomedics, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Innate Pharma S.A.

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Les Laboratoires Servier SAS

LFB S.A.

Lymphocyte Activation Technologies, S.A.

Medicenna Therapeutics, Inc.

Millennium Pharmaceuticals, Inc.

MorphoSys AG

Novartis AG

Oncternal Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd.

Portola Pharmaceuticals, Inc.

Sanofi

TG Therapeutics, Inc.

Threshold Pharmaceuticals, Inc.

Tragara Pharmaceuticals, Inc.

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(INCB-039110 + INCB-040093) - Drug Profile

4SC-202 - Drug Profile

acalabrutinib - Drug Profile

ACP-319 - Drug Profile

afuresertib hydrochloride - Drug Profile

AGS-67E - Drug Profile

AR-42 - Drug Profile

AT-7519 - Drug Profile

AZD-6738 - Drug Profile

BI-836826 - Drug Profile

BMS-986016 - Drug Profile

buparlisib hydrochloride - Drug Profile

CBM-C19.1 - Drug Profile

CBM-C20.1 - Drug Profile

CC-122 - Drug Profile

Cellular Immunotherapy for Chronic Lymphocytic Leukemia - Drug Profile

Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile

cerdulatinib - Drug Profile

duvelisib - Drug Profile

evofosfamide - Drug Profile

HMPL-523 - Drug Profile

IMGN-529 - Drug Profile

IMMU-114 - Drug Profile

JCAR-014 - Drug Profile

JCAR-015 - Drug Profile

lirilumab - Drug Profile

MDNA-56 - Drug Profile

monalizumab - Drug Profile

MOR-208 - Drug Profile

nivolumab - Drug Profile

obinutuzumab - Drug Profile

pilaralisib - Drug Profile

S-055746 - Drug Profile

selinexor - Drug Profile

spebrutinib besylate - Drug Profile

TAK-659 - Drug Profile

TG-02 - Drug Profile

TGR-1202 - Drug Profile

tisagenlecleucel-T - Drug Profile

ublituximab - Drug Profile

UC-961 - Drug Profile

ulocuplumab - Drug Profile

urelumab - Drug Profile

venetoclax - Drug Profile

Refractory Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates

Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects

Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products

Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2016

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H1 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2016

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
4SC AG
AbbVie Inc.
Arno Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
F. Hoffmann-La Roche Ltd.
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Innate Pharma S.A.
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Les Laboratoires Servier SAS
LFB S.A.
Lymphocyte Activation Technologies, S.A.
Medicenna Therapeutics, Inc.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Novartis AG
Oncternal Therapeutics, Inc.
Ono Pharmaceutical Co., Ltd.
Portola Pharmaceuticals, Inc.
Sanofi
TG Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll